XML 58 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
12 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
Schedule of Geographic Area Information

 

a.

Geographic Area Information:

 

 

 

Israel

 

 

Canada*

 

 

U.S.A.

 

 

Other

 

 

Consolidated

 

Year ended March 31, 2017 and as of

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales to unaffiliated customers **

 

$

29,200

 

 

$

57,621

 

 

$

785,319

 

 

$

7,247

 

 

$

879,387

 

Long-lived assets ***

 

$

101,111

 

 

$

55,154

 

 

$

36,940

 

 

$

 

 

$

193,205

 

Year ended March 31, 2016 and as of

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales to unaffiliated customers **

 

$

22,963

 

 

$

56,605

 

 

$

865,224

 

 

$

5,959

 

 

$

950,751

 

Long-lived assets ***

 

$

92,284

 

 

$

49,936

 

 

$

32,771

 

 

$

 

 

$

174,991

 

Year ended March 31, 2015 and as of

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales to unaffiliated customers **

 

$

22,157

 

 

$

55,452

 

 

$

777,191

 

 

$

8,144

 

 

$

862,944

 

Long-lived assets ***

 

$

88,804

 

 

$

46,876

 

 

$

36,755

 

 

$

1,020

 

 

$

173,455

 

 

*

Includes operations in both Canada and Cayman Islands.

**

Based on customer’s location.

***

Includes property, plant and equipment, net; goodwill and intangible assets, net.

Schedule of Sales by Therapeutic Category

 

c.

Sales by therapeutic category, as a percentage of total net sales for the years ended March 31, 2017, 2016 and 2015, were as follows:

 

 

 

Year ended March 31,

 

Category

 

2017

 

 

2016

 

 

2015

 

Dermatological and topical

 

 

64

%

 

 

66

%

 

 

66

%

Neuropsychiatric

 

 

18

%

 

 

20

%

 

 

16

%

Anti-inflammatory

 

 

8

%

 

 

3

%

 

 

5

%

Cardiovascular

 

 

6

%

 

 

8

%

 

 

8

%

Other

 

 

4

%

 

 

3

%

 

 

5

%

Total

 

 

100

%

 

 

100

%

 

 

100

%